Patents by Inventor Barbara J. Gour

Barbara J. Gour has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20030082166
    Abstract: Modulating agents for inhibiting or enhancing nonclassical cadherin mediated cell adhesion are provided. The modulating agents comprise one or more of: (a) a peptide sequence that is at least 50% identical to a nonclassical cadherin CAR sequence; (b) a non-peptide mimetic of a nonclassical cadherin CAR sequence; (c) a substance, such as an antibody or antigen-binding fragment thereof, that specifically binds a nonclassical cadherin CAR sequence; and/or (d) a polynucleotide encoding a polypeptide that comprises a nonclassical cadherin CAR sequence or analogue thereof. Methods for using such modulating agents for modulating nonclassical cadherin-mediated cell adhesion in a variety of contexts are also provided.
    Type: Application
    Filed: December 3, 2001
    Publication date: May 1, 2003
    Applicant: Adherex Technologies, Inc.
    Inventors: Orest W. Blaschuk, Barbara J. Gour
  • Patent number: 6551994
    Abstract: Modulating agents for inhibiting an interaction between &agr;-catenin and &bgr;-catenin are provided. The modulating agents comprise one or more of: (a) a &bgr;-catenin HAV motif; (b) a peptide analogue or mimetic of a &bgr;-catenin HAV motif; or (c) an antibody or antigen-binding fragment thereof that specifically binds to a &bgr;-catenin HAV motif. Methods for using such modulating agents for inhibiting cadherin-mediated cell adhesion in a variety of contexts are also provided.
    Type: Grant
    Filed: April 8, 1998
    Date of Patent: April 22, 2003
    Assignee: McGill University
    Inventors: Orest W. Blaschuk, Barbara J. Gour
  • Publication number: 20030065136
    Abstract: Cyclic peptides comprising a cadherin cell adhesion recognition sequence HAV, and compositions comprising such cyclic peptides, are provided. Methods for using such peptides for modulating cadherin-mediated cell adhesion in a variety of contexts are also provided.
    Type: Application
    Filed: March 22, 2002
    Publication date: April 3, 2003
    Applicant: McGill University
    Inventors: Orest W. Blaschuk, Barbara J. Gour, Riaz Farookhi, Anmar Ali
  • Publication number: 20030027761
    Abstract: Methods for using modulating agents to enhance or inhibit junctional adhesion molecule (JAM)-mediated cell adhesion in a variety of in vivo and in vitro contexts are provided. The modulating agents comprise at least one JAM cell adhesion recognition sequence or an antibody or fragment thereof that specifically binds thee JAM cell adhesion recognition sequence. Modulating agents may additionally comprise one or more cell adhesion recognition sequences recognized by other adhesion molecules. Such modulating agents may, but need not, be linked to a targeting agent, drug and/or support material.
    Type: Application
    Filed: April 8, 2002
    Publication date: February 6, 2003
    Applicant: Adherex Technologies, Inc.
    Inventors: Orest W. Blaschuk, James Matthew Symonds, Barbara J. Gour
  • Publication number: 20030013655
    Abstract: Methods for using modulating agents to enhance or inhibit cadherin-mediated cell adhesion in a variety of in vivo and in vitro contexts are provided. In particular, the modulating agents may be used in the therapy of multiple sclerosis and other demyelinating diseases. The modulating agents comprise at least one cadherin cell adhesion recognition sequence (HAV) or an antibody or fragment thereof that specifically binds to a cadherin cell adhesion recognition sequence. Modulating agents may additionally comprise one or more cell adhesion recognition sequences recognized by other adhesion molecules. Such modulating agents may, but need not, be linked to a targeting agent, drug and/or support material.
    Type: Application
    Filed: February 5, 2001
    Publication date: January 16, 2003
    Inventors: Orest W. Blaschuk, Barbara J. Gour
  • Publication number: 20020193294
    Abstract: Methods for using modulating agents to enhance or inhibit claudin-mediated cell adhesion in a variety of in vivo and in vitro contexts are provided. Within certain embodiments, the modulating agents may be used to increase blood/brain barrier permeability. The modulating agents comprise at least one claudin cell adhesion recognition sequence or an antibody or fragment thereof that specifically binds the claudin cell adhesion recognition sequence. Modulating agents may additionally comprise one or more cell adhesion recognition sequences recognized by other adhesion molecules. Such modulating agents may, but need not, be linked to a targeting agent, drug and/or support material.
    Type: Application
    Filed: November 3, 1998
    Publication date: December 19, 2002
    Inventors: OREST W. BLASCHUK, JAMES MATTHEW SYMONDS, BARBARA J. GOUR
  • Publication number: 20020168761
    Abstract: Peptidomimetics of cyclic peptides, and compositions comprising such peptidomimetics are provided. The peptidomimetics have a three-dimensional structure that is substantially similar to a three-dimensional structure of a cyclic peptide that comprises a cadherin cell adhesion recognition sequence HAV. Methods for using such peptidomimetics for modulating cadherin-mediated cell adhesion in a variety of contexts are also provided.
    Type: Application
    Filed: January 24, 2001
    Publication date: November 14, 2002
    Inventors: Barbara J. Gour, Orest W. Blaschuk, Anmar Ali, Feng Ni, Zhigang Chen, Stephanie D. Michaud, Shoameng Wang, Zenjian Hu
  • Publication number: 20020169106
    Abstract: Agents for inhibiting cancer metastasis are provided. The methods comprise administering to a patient an antimetastatic agent that comprises one or more of: (a) a peptide sequence that is at least 50% identical to an OB-cadherin CAR sequence; (b) a non-peptide mimetic of an OB-cadherin CAR sequence; (c) a substance, such as an antibody or antigen-binding fragment thereof, that specifically binds an OB-cadherin CAR sequence; and/or (d) a polynucleotide encoding a polypeptide that comprises an OB-cadherin CAR sequence or analogue thereof.
    Type: Application
    Filed: March 8, 1999
    Publication date: November 14, 2002
    Inventors: OREST W. BLASCHUK, STEPHEN BYERS, BARBARA J. GOUR, JAMES MATTHEW SYMONDS
  • Patent number: 6472368
    Abstract: Modulating agents and methods for enhancing or inhibiting cadherin-mediated functions are provided. The modulating agents comprise at least an HAV binding motif, an analogue or peptidomimetic thereof, or an antibody or fragment thereof that specifically binds to such a motif. Modulating agents may additionally comprise one or more cell adhesion recognition sequences recognized by cadherins and/or other adhesion molecules. Such modulating agents may, but need not, be linked to a targeting agent, drug and/or support material.
    Type: Grant
    Filed: July 9, 1999
    Date of Patent: October 29, 2002
    Assignee: Adherex Technologies, Inc.
    Inventors: Patrick Doherty, Orest W. Blaschuk, Barbara J. Gour
  • Patent number: 6472367
    Abstract: Modulating agents for inhibiting or enhancing OB-cadherin mediated cell adhesion are provided. The modulating agents comprise one or more of: (a) an OB-cadherin CAR sequence; (b) a peptide analogue or peptidomimetic thereof; (c) an antibody or antigen-binding fragment thereof that specifically binds an OB-cadherin CAR sequence; and/or (d) a polynucleotide encoding any of the foregoing peptide sequences. Methods for using such modulating agents for modulating OB-cadherin-mediated cell adhesion in a variety of contexts are also provided.
    Type: Grant
    Filed: May 5, 1998
    Date of Patent: October 29, 2002
    Assignee: Adherex Technologies, Inc.
    Inventors: Orest W. Blaschuk, James Matthew Symonds, Barbara J. Gour
  • Publication number: 20020151475
    Abstract: Cyclic peptides and compositions comprising such cyclic peptides are provided. The cyclic peptides comprise a cadherin cell adhesion recognition sequence HAV. Methods for using such peptides and compositions for modulating cadherin-mediated cell adhesion in a variety of contexts are also provided.
    Type: Application
    Filed: December 4, 2001
    Publication date: October 17, 2002
    Applicant: McGill University
    Inventors: Orest W. Blaschuk, Barbara J. Gour
  • Patent number: 6465427
    Abstract: Cyclic peptides comprising a cadherin cell adhesion recognition sequence HAV, and compositions comprising such cyclic peptides, are provided. Methods for using such peptides for modulating cadherin-mediated cell adhesion in a variety of contexts are also provided.
    Type: Grant
    Filed: December 10, 1999
    Date of Patent: October 15, 2002
    Assignee: McGill University
    Inventors: Orest W. Blaschuk, Barbara J. Gour, Riaz Farookhi, Anmar Ali
  • Publication number: 20020146687
    Abstract: Methods for diagnosing cancer, such as prostate, ovarian or breast cancer, as well as leukemia, are provided. Such methods may employ binding agents, such as antibodies or CAR sequences of OB-cadherin or N-cadherin, that specifically bind to OB-cadherin or N-cadherin, or polynucleotides that hybridize to a polynucleotide encoding OB-cadherin or N-cadherin. Also provided are methods for monitoring the progression of a cancer and to evaluate the metastatic potential of a cancer.
    Type: Application
    Filed: May 5, 1999
    Publication date: October 10, 2002
    Inventors: OREST W. BLASCHUK, JAMES MATTHEW SYMONDS, STEPHEN BYERS, BARBARA J. GOUR
  • Publication number: 20020123044
    Abstract: Methods for diagnosing cancer, such as prostate, ovarian or breast cancer, as well as leukemia, are provided. Such methods may employ binding agents, such as antibodies or CAR sequences of OB-cadherin or N-cadherin, that specifically bind to OB-cadherin or N-cadherin, or polynucleotides that hybridize to a polynucleotide encoding OB-cadherin or N-cadherin. Also provided are methods for monitoring the progression of a cancer and to evaluate the metastatic potential of a cancer.
    Type: Application
    Filed: January 20, 1999
    Publication date: September 5, 2002
    Inventors: OREST W. BLASCHUK, JAMES MATTHEWS SYMONDS, STEPHEN BYERS, BARBARA J. GOUR
  • Patent number: 6433149
    Abstract: Agents for inhibiting cancer metastasis are provided. The methods comprise administering to a patient an antimetastatic agent that comprises one or more of: (a) a peptide sequence that is at least 50% identical to an OB-cadherin CAR sequence; (b) a non-peptide mimetic of an OB-cadherin CAR sequence; (c) a substance, such as an antibody or antigen-binding fragment thereof, that specifically binds an OB-cadherin CAR sequence; and/or (d) a polynucleotide encoding a polypeptide that comprises an OB-cadherin CAR sequence or analogue thereof.
    Type: Grant
    Filed: May 5, 1999
    Date of Patent: August 13, 2002
    Assignee: Adherex Technologies, Inc.
    Inventors: Orest W. Blaschuk, James Matthew Symonds, Stephen Byers, Barbara J. Gour
  • Patent number: 6417325
    Abstract: Agents that inhibit the development of cancer and tumor growth are provided. Such agents comprise a classical cadherin CAR sequence HAV within a cyclic peptide ring, and may be used to prevent or treat cancer.
    Type: Grant
    Filed: July 20, 1999
    Date of Patent: July 9, 2002
    Assignee: McGill University
    Inventors: Orest W. Blaschuk, Barbara J. Gour, Riaz Farookhi
  • Patent number: 6391855
    Abstract: Methods for using modulating agents to enhance or inhibit junctional adhesion molecule (JAM)-mediated cell adhesion in a variety of in vivo and in vitro contexts are provided. The modulating agents comprise at least one JAM cell adhesion recognition sequence or an antibody or fragment thereof that specifically binds the JAM cell adhesion recognition sequence. Modulating agents may additionally comprise one or more cell adhesion recognition sequences recognized by other adhesion molecules. Such modulating agents may, but need not, be linked to a targeting agent, drug and/or support material.
    Type: Grant
    Filed: June 2, 1999
    Date of Patent: May 21, 2002
    Assignee: Adherex Technologies, Inc.
    Inventors: Orest W. Blaschuk, James Matthew Symonds, Barbara J. Gour
  • Patent number: 6358920
    Abstract: Modulating agents for inhibiting or enhancing nonclassical cadherin mediated cell adhesion are provided. The modulating agents comprise one or more of: (a) a peptide sequence that is at least 50% identical to a nonclassical cadherin CAR sequence; (b) a non-peptide mimetic of a nonclassical cadherin CAR sequence; (c) a substance, such as an antibody or antigen-binding fragment thereof, that specifically binds a nonclassical cadherin CAR sequence; and/or (d) a polynucleotide encoding a polypeptide that comprises a nonclassical cadherin CAR sequence or analogue thereof. Methods for using such modulating agents for modulating nonclassical cadherin-mediated cell adhesion in a variety of contexts are also provided.
    Type: Grant
    Filed: November 6, 1998
    Date of Patent: March 19, 2002
    Assignee: Adherex Technologies
    Inventors: Orest W. Blaschuk, Barbara J. Gour
  • Patent number: 6346512
    Abstract: Cyclic peptides and compositions comprising such cyclic peptides are provided. The cyclic peptides comprise a cadherin cell adhesion recognition sequence HAV. Methods for using such peptides and compositions for modulating cadherin-mediated cell adhesion in a variety of contexts are also provided.
    Type: Grant
    Filed: February 10, 1999
    Date of Patent: February 12, 2002
    Assignee: McGill University
    Inventors: Orest W. Blaschuk, Barbara J. Gour
  • Patent number: 6333307
    Abstract: Modulating agents comprising cyclic peptides, and compositions comprising such modulating agents are provided. The cyclic peptides comprise a cadherin cell adhesion recognition sequence HAV. Methods for using such peptides and compositions for modulating and/or directing neurite outgrowth in a variety of contexts are also provided.
    Type: Grant
    Filed: February 12, 1999
    Date of Patent: December 25, 2001
    Assignee: McGill University
    Inventors: Orest W. Blaschuk, Barbara J. Gour